New Concepts for Targeted Systemic Therapy in Breast Cancer

Breast cancer is characterized by a fundamental heterogeneity, the extent of which has been demonstrated in numerous scientific studies. Currently, breast cancer is divided into three major subgroups: luminal, Her-2 positive, and triple negative breast cancer. Despite considerable advances in the therapy of patients with breast cancer, further optimization of current therapeutic strategies is necessary and possible. While the therapy of luminal and Her-2 positive breast cancers focuses on preventing and overcoming tumoral resistance, research into triple negative breast cancer concentrates on developing and establishing novel targeted therapeutic agents.